<DOC>
	<DOCNO>NCT02102698</DOCNO>
	<brief_summary>Tourette 's Syndrome neurological disease characterize motor vocal tic . It hypothesize abnormal interaction dopamine receptor may cause tic . The purpose study test hypothesis drug ( ecopipam ) selectively block dopamine D1/D5 receptor reduce frequency severity tic .</brief_summary>
	<brief_title>Ecopipam Treatment Tourette 's Syndrome Subjects 7-17 Years</brief_title>
	<detailed_description>This double blind , randomize , placebo-controlled crossover study determine whether ecopipam reduce symptom Tourette 's child age 7-17 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Ecopipam</mesh_term>
	<criteria>• Subjects must Tourette 's Syndrome ( TS ) base clinicianadministered Diagnostic Confidence Index ( DCI ) TS . Subjects must exhibit motor vocal tic . Subjects must minimum score 20 Screening Baseline ( prior first treatment ) Yale Global Tic Severity Scale . Subjects must age ( ≥ 7 &lt; 18 year age ) Subjects must weigh ≥ 20 kg ( 45 lb ) Adolescent females childbearing potential sexually active must use effective contraception ( i.e. , oral contraceptive , intrauterine device , double barrier method condom spermicide ) agree continue use contraception duration participation study . They must also agree use contraception 30 day last dose study drug . Sexually active male subject must use barrier method contraception study agree continue use male contraception least 30 day last dose study drug . Subject 's parent legal guardian must execute write informed consent . Subject must execute write informed assent . Subjects unstable medical illness clinically significant abnormality laboratory test , ECG Screening . Subjects major depressive episode past 2 year Subjects history attempt suicide Subjects clinically significant suicidality ( base Columbia Suicide Rating Scale ( CSSRS ) Subjects firstdegree relative major depressive episode result psychiatric hospitalization , attempted/ complete suicide exception hospitalization postpartum depression . Subjects history seizure ( exclude febrile seizure occur &gt; 2 year past ) Subjects myocardial infarction within 6 month . Girls currently pregnant lactate . Subjects need medication ( ecopipam ) possible effect TS symptom ( i.e. , lithium , psychostimulants ) Subjects need medication would unfavorable interaction ecopipam , e.g. , dopamine antagonist agonist [ include bupropion ] , tetrabenazine , monoamine oxidase inhibitor . Subjects lifetime history bipolar disorder type I II , dementia , schizophrenia , psychotic disorder determine Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders 4th Edition ( DSMIV ) AxisI Disorders ( SCID ) . Subjects current recent ( past 3 month ) DSMIV substance abuse dependence ( exception nicotine ) . Subjects positive urine drug screen ( cocaine , amphetamine , methamphetamine , tetrahydrocannabinol ( THC ) , benzodiazepine , barbiturate , phencyclidine ( PCP ) , opiates ) Screening . Subjects urine positive benzodiazepine and/or marijuana ( i.e. , user abuser base DSMIV criterion ) may eligible . Subjects previous treatment ecopipam . Subjects treatment : investigational medication within 3 month start study depot neuroleptic within 3 month start study psychotropics possible effect TS symptom ( i.e. , lithium , tetrabenazine ) within 2 week prior Screening . oral neuroleptic within 4 week selective serotonin reuptake inhibitor unless dosage stable minimum 4 week prior study start prescribe relieve neurological sign TS</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Tourette 's Syndrome</keyword>
	<keyword>Ecopipam</keyword>
	<keyword>D1 Receptor</keyword>
	<keyword>Phase 2</keyword>
</DOC>